Eli Lilly and Company (LLY) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Eli Lilly and Company (NYSE: LLY) in the last few weeks:

• 11/4/2024 – Eli Lilly and Company was upgraded by analysts at Redburn Atlantic to a “hold” rating.
• 11/4/2024 – Eli Lilly and Company had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $1,025.00 to $1,015.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Eli Lilly and Company had its price target lowered by analysts at Barclays PLC from $1,025.00 to $975.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Eli Lilly and Company had its price target lowered by analysts at Bank of America Co. from $1,150.00 to $1,100.00. They now have a “buy” rating on the stock.
• 10/25/2024 – Eli Lilly and Company had its price target raised by analysts at Citigroup Inc. from $1,060.00 to $1,250.00. They now have a “buy” rating on the stock.
• 10/17/2024 – Eli Lilly and Company is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $1,100.00 price target on the stock.
• 10/10/2024 – Eli Lilly and Company had its price target raised by analysts at Truist Financial Co. from $1,000.00 to $1,033.00. They now have a “buy” rating on the stock.
• 10/3/2024 – Eli Lilly and Company had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $1,025.00 price target on the stock.
• 9/16/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company Price Performance

LLY stock opened at $811.30 on Thursday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $770.18 billion, a PE ratio of 87.71, a price-to-earnings-growth ratio of 3.10 and a beta of 0.43. The business has a 50 day simple moving average of $891.02 and a 200-day simple moving average of $870.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LLY. International Assets Investment Management LLC grew its holdings in shares of Eli Lilly and Company by 87,091.7% in the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company’s stock worth $11,041,631,000 after acquiring an additional 12,448,888 shares during the period. Swedbank AB purchased a new stake in Eli Lilly and Company during the first quarter worth $932,797,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after purchasing an additional 1,133,810 shares during the last quarter. Pathway Financial Advisers LLC grew its holdings in Eli Lilly and Company by 92,759.9% in the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company’s stock valued at $905,774,000 after purchasing an additional 1,021,287 shares during the last quarter. Finally, Wulff Hansen & CO. increased its position in shares of Eli Lilly and Company by 90,438.0% in the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock valued at $848,403,000 after buying an additional 936,033 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.